CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Ironshore Pharmaceuticals Inc

Colin Boatwright, CIO

How Technology is Disrupting the Pharma and Life Sciences Industry

Colin Boatwright

Colin Boatwright

The Pharma and Life Sciences have a reputation of lagging behind in certain technology areas, either because of fears around regulatory concerns or the cost of migrating legacy applications. Founded or not, companies with a legacy set of applications face a challenge of how to move to modern solutions like Cloud, robotic process automation, micro-services, AI/ML, AR/ VR, and the host of other acronyms you read about daily.


Add to those concerns, from a pure financial point of view, it rarely makes sense: retiring a fully capitalized system with very few resources supporting it cannot be justified in a vacuum. But the reality is that your legacy systems are the anchor that will keep you moving forward.


It’s more than the fact that newly hired employees may prefer to work on more modern applications. It’s more than the issue of silos working separately, and not overall outcomes based. Legacy applications will always be the long pole in the tent.


You can certainly put in an integration platform, but you will always find yourself throttled by the underlying legacy systems. So where do you start?


First, start with a vision … something akin to “We will be 100% cloud-based by 2023” and pivot your entire organization to that goal. Don’t create multiple separate initiatives with as many architects. Instead, create a cross-functional group that understands the vision and has the technical abilities to create.


This may mean pulling people out of their groups into a “Vision 2023” group. Focus them on how to power outcomes, getting your data ready for future technologies, and blueprinting thigs like AI/ML but delivering on the practical. Whiteboard your pain points and divide into two categories: “Simple” and “Complex.”


The simple should be simple; complex should be possible. Often, we make the simple complex and the complex impossible. For the “Simple” ones, just do them.


Don’t debate, don’t create committees, don’t let internal politics stop you.


If you cannot get past the simple, you’ll never get to the complex. For the “Complex” ones, break them down so they can be simple and put them out on a Horizon Chart: Horizon 1-3. Spend time on what Horizon 3 should look like, but agree to a clear vision on how to get to your end-state. Getting from “here” to “there” is never onestep, but a journey. It is, however, a journey needs that needs an endpoint.


As you make your journey to cloud-only, new initiatives should be cloud-first … don’t go and create “new legacy” applications simple because you don’t think your organization is ready. You can make it ready thru leadership. Use new initiatives as an opportunity for “mini disruptions.”


It’s not a technology issue but a cultural one. Your SOPs can survive the move to the Cloud, don’t think otherwise. The major cloud players have already figured it out better than you can … or at least, have some trust that they have. Pick one of the major players and let that be your architecture: don’t get lost in the “best in breed” mentality, pick the environment that works best for you. Mostly a Microsoft shop? Go Azure and move on. Same thought process with Google and AWS.


Finally, remember modernizing IT never stops. The legacy applications of today were the forward-thinking ones of yesterday. As you move away from your legacy applications, legacy data centers, legacy business process, legacy anything, remember that what you replace it with has the danger of becoming the next evil legacy application. So never forget to keep your applications regularly updated, exploring the next “new” thing and decide if you should advance your applications in that direction.


Small, iterative upgrades will keep you current and avoid the situation many are in today with systems that were left on auto pilot, but have nowhere left to go.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cioviewpoint/how-technology-is-disrupting-the-pharma-and-life-sciences-industry-nwid-25.html